NasdaqCM - Nasdaq Real Time Price USD

BioLineRx Ltd. (BLRX)

3.1700
-0.0300
(-0.94%)
At close: May 9 at 4:00:00 PM EDT
3.1500
-0.02
(-0.63%)
After hours: May 9 at 4:05:06 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
28,940
28,940
4,800
0
0
Cost of Revenue
9,263
9,263
3,692
0
0
Gross Profit
19,677
19,677
1,108
0
0
Operating Expense
38,829
38,829
44,099
29,157
24,777
Operating Income
-19,152
-19,152
-42,991
-29,157
-24,777
Net Non Operating Interest Income Expense
-7,299
-7,299
-162
-1,118
-729
Other Income Expense
17,230
17,230
-17,461
5,324
-1,548
Pretax Income
-9,221
-9,221
-60,614
-24,951
-27,054
Net Income Common Stockholders
-9,221
-9,221
-60,614
-24,951
-27,054
Diluted NI Available to Com Stockholders
-9,221
-9,221
-60,614
-24,951
-27,054
Basic EPS
-12.00
-6.00
-36.00
-18.00
-24.00
Diluted EPS
-12.00
-6.00
-36.00
-18.00
-24.00
Basic Average Shares
1,901.1520
1,996.8460
1,605.6090
1,289.9280
1,104.8890
Diluted Average Shares
1,901.1520
1,996.8460
1,605.6090
1,289.9280
1,104.8890
Total Operating Income as Reported
-20,408
-20,408
-49,694
-29,157
-24,777
Total Expenses
48,092
48,092
47,791
29,157
24,777
Net Income from Continuing & Discontinued Operation
-9,221
-9,221
-60,614
-24,951
-27,054
Normalized Income
-26,981
-26,981
-42,918
-31,030
-25,400
Interest Income
1,820
1,820
2,007
694
277
Interest Expense
9,074
9,074
2,144
1,786
984
Net Interest Income
-7,299
-7,299
-162
-1,118
-729
EBIT
-147
-147
-58,470
-23,165
-26,070
EBITDA
3,918
3,918
-57,086
-22,511
-25,367
Reconciled Cost of Revenue
5,538
5,538
2,659
0
0
Reconciled Depreciation
4,065
4,065
1,384
654
703
Net Income from Continuing Operation Net Minority Interest
-9,221
-9,221
-60,614
-24,951
-27,054
Total Unusual Items Excluding Goodwill
17,760
17,760
-17,696
6,079
-1,654
Total Unusual Items
17,760
17,760
-17,696
6,079
-1,654
Normalized EBITDA
-13,842
-13,842
-39,390
-28,590
-23,713
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 7/27/2011

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CANF Can-Fite BioPharma Ltd.
1.1100
-0.45%
 
PLX Protalix BioTherapeutics, Inc.
1.7200
-40.48%
 
PLUR Pluri Inc.
5.75
+8.29%
 
BCLI Brainstorm Cell Therapeutics Inc.
1.1800
-3.28%
 
ENLV Enlivex Therapeutics Ltd.
1.0200
-2.86%
 
EVGN Evogene Ltd.
1.1325
+0.22%
 
PYPD PolyPid Ltd.
2.7700
-0.72%
 
OGEN Oragenics, Inc.
0.1686
-6.33%
 
NLSP NLS Pharmaceutics AG
1.6400
-3.53%
 
CGEN Compugen Ltd.
1.2600
-2.33%